Publications by authors named "Kunal Taskar"

Claim this Profile
S
Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug-Drug Interaction Predictions.
Kunal S Taskar, Pradeep Sharma, Karen Rowland Yeo

Clin Pharmacol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically-Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges.
James W T Yates, Michael Zientek, Kunal S Taskar, Wen Lin, Tycho Heimbach

CPT Pharmacometrics Syst Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of brain penetration and tumor accumulation of niraparib and olaparib: insights from multimodal imaging in preclinical models.
M Reid Groseclose, Jeremy A Barry, Tina Skedzielewski, Yongle Pang, Yinghe Li, Kunal Taskar

Sci Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging in vitro and clinical data: Experimental insights into the IC variability of dolutegravir as an organic cation transporter 2 inhibitor.
Tomoki Koishikawa, Yukana Tomoda, Toshiaki Tsuchitani, Kunal Taskar, Kenta Yoshida

Drug Metab Dispos· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically Based Pharmacokinetic Modeling of Phosphate Prodrugs─Case Studies: Fostemsavir and Fostamatinib.
Konstantinos Stamatopoulos, Nena Mistry, Kunal Taskar, Farzaneh Salem, James M Butler

Mol Pharm· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matrix Approach Assessment of Cabotegravir Drug-Drug Interactions with OAT1/OAT3 Substrates and UGT1A1/UGT1A9 Inhibitors Using Physiologically-Based Pharmacokinetic Modeling.
Helen Tracey, Simon T Bate, Susan Ford, Parul Patel, Jackie Bloomer, Kunal S Taskar

Pharmaceutics· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective.
Micaela B Reddy, Tamara D Cabalu, Loeckie de Zwart, Diane Ramsden, Martin E Dowty, Kunal S Taskar

Clin Pharmacol Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Cimetidine and Dolutegravir on the Endogenous Drug-Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers.
Tomoki Koishikawa, Kaku Fujiwara, Kunal Taskar, Maciej J Zamek-Gliszczynski, Kenta Yoshida

Clin Pharmacol Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy.
Farzaneh Salem, Dung Nguyen, Mark Bush, Katy P Moore, Jennypher Mudunuru, Kunal S Taskar

CPT Pharmacometrics Syst Pharmacol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program.
Gerald R Galluppi, Malidi Ahamadi, Souvik Bhattacharya, Nageshwar Budha, Ferdous Gheyas, Kunal Taskar

Clin Pharmacol Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No dose adjustment of metformin or substrates of organic cation transporters (OCT)1 and OCT2 and multidrug and toxin extrusion protein (MATE)1/2K with fostemsavir coadministration based on modeling approaches.
Dung Nguyen, Xiusheng Miao, Kunal Taskar, Mindy Magee, Pete Gorycki

Pharmacol Res Perspect· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survey of Pharmaceutical Industry's Best Practices around In Vitro Transporter Assessment and Implications for Drug Development: Considerations from the International Consortium for Innovation and Quality for Pharmaceutical Development Transporter Working Group.
Helen E Rollison, Pallabi Mitra, Hugues Chanteux, Zhizhou Fang, Xiaomin Liang, Kunal Taskar

Drug Metab Dispos· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically-based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug-drug interactions.
Gareth J Lewis, Deepak Ahire, Kunal S Taskar

CPT Pharmacometrics Syst Pharmacol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innovations, Opportunities, and Challenges for Predicting Alteration in Drug-Metabolizing Enzyme and Transporter Activity in Specific Populations.
Paresh P Chothe, Vikram Arya, Bhagwat Prasad, Diane Ramsden, Kunal Taskar

Drug Metab Dispos· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug.
Farzaneh Salem, Ali Nimavardi, Jennypher Mudunuru, Debra Tompson, Jackie Bloomer, Kunal S Taskar

CPT Pharmacometrics Syst Pharmacol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective.
Niresh Hariparsad, Diane Ramsden, Kunal Taskar, Justine Badée, Karthik Venkatakrishnan

Clin Pharmacol Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective.
Xiaoyan Chu, Bhagwat Prasad, Sibylle Neuhoff, Kenta Yoshida, James Steven Leeder, Kunal Taskar

Clin Pharmacol Ther· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective.
Kunal S Taskar, Xinning Yang, Sibylle Neuhoff, Mitesh Patel, Kenta Yoshida

Clin Pharmacol Ther· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney.
Ryuta Asaumi, Ken-Ichi Nunoya, Yoshiyuki Yamaura, Kunal S Taskar, Yuichi Sugiyama

CPT Pharmacometrics Syst Pharmacol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions.
Tatsuki Mochizuki, Maciej J Zamek-Gliszczynski, Kenta Yoshida, Jialin Mao, Kunal Taskar

Clin Pharmacol Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs.
Tatsuki Mochizuki, Yasunori Aoki, Takashi Yoshikado, Kenta Yoshida, Yurong Lai, Kunal Taskar

Clin Transl Sci· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically-based Pharmacokinetic (PBPK) Modelling of Transporter Mediated Drug Absorption, Clearance and Drug-drug Interactions.
Kunal S Taskar, Isobel Harada, Ravindra V Alluri

Curr Drug Metab· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program.
Gerald R Galluppi, Satjit Brar, Luzelena Caro, Yuan Chen, Nicolas Frey, Kunal S Taskar

Clin Pharmacol Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When special populations intersect with drug-drug interactions: Application of physiologically-based pharmacokinetic modeling in pregnant populations.
Caroline Sychterz, Aleksandra Galetin, Kunal S Taskar

Biopharm Drug Dispos· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intestinal P-gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications.
Maciej J Zamek-Gliszczynski, Mitesh Patel, Xinning Yang, Justin D Lutz, Xiaoyan Chu, Kunal S Taskar

Clin Pharmacol Ther· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis